A comparison of the lived experiences among extended and long-term young adult cancer survivors

Relugolix offers a more convenient and flexible treatment option than injectable therapies. Credit: NICE. The UK National Institute for Health and Care Excellence (Nice) has

Pfiz­er is set to stop con­struc­tion of a man­u­fac­tur­ing fa­cil­i­ty start­ed by Seagen in Wash­ing­ton state, with af­fect­ed em­ploy­ees pos­si­bly mov­ing to oth­er fa­cil­i­ties, a

Share this article In the Phase II DeLLphi-301 trial in advanced SCLC patients, tarlatamab offered antitumour activity with a lasting response. Credit: Kateryna Kon /